rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VVOS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates

      Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +76.67% and +17.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 16Yahoo FinanceVVOS
      Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance
      Nov 16Investing.comVVOS
      CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

      This release removes the mention of Cleveland Clinic Weston.Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease patientsVERO BEACH, FL / ACCESS Newswire / October 29, 2026 / SOD Sciences, Inc.

      Oct 29Yahoo FinanceVVOS
      Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

      LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026

      Oct 21Yahoo FinanceVVOS
      SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
      Oct 20Yahoo FinanceVVOS
      Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test
      Oct 19Yahoo FinanceVVOS
      Vivos Therapeutics acquires stake in SOD Sciences
      Oct 19Investing.comVVOS
      12 Health Care Stocks Moving In Monday's After-Market Session - Vivos Therapeutics (NASDAQ:VVOS), SCWorx

      Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved

      Oct 19BenzingaVVOS
      Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
      Oct 19Yahoo FinanceVVOS
      Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test
      Oct 16Yahoo FinanceVVOS
      Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

      Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic AlliancesLITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today ann

      Oct 15Yahoo FinanceVVOS
      Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate

      Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.

      Sep 29Yahoo FinanceVVOS
      Vivos Therapeutics plans $3.6M annual cost reduction
      Sep 29Investing.comVVOS
      Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

      Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line RevenueLITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execut

      Sep 29Yahoo FinanceVVOS
      Vivos exchanges $2.9m debt for common stock with Streeterville
      Sep 8Investing.comVVOS
      Vivos Therapeutics Announces Material Debt Reduction

      Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t

      Sep 8Yahoo FinanceVVOS
      Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

      Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailVVOS
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Aug 31BenzingaRDHLVVOS
      Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results
      Aug 31BenzingaVVOSSAIC
      Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
      Aug 31BenzingaAEHLVVOSWBUY
      Vivos Therapeutics partners with Florida cardiology group for sleep center
      Aug 28Investing.comVVOS
      Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

      Physician-Aligned Collaboration to Support a Regional Sleep & Airway Medicine Center in Palm Beach CountyLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, to

      Aug 28Yahoo FinanceVVOS
      Vivos Therapeutics reports 212% rise in Nevada patient referrals
      Aug 25Investing.comVVOS
      Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

      Average Weekly New Patient Referrals into Vivos’ Nevada Sleep & Airway Medicine Centers Rose 212% Over the Past Six Weeks from the Prior Six WeeksLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, t

      Aug 25Yahoo FinanceVVOS
      12 Health Care Stocks Moving In Tuesday's After-Market Session - Alector (NASDAQ:ALEC), NeuroSense Therap

      Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increased

      Aug 25BenzingaAKANALECMRKRNRSNSYREVVOS

      This is the newest page. Registered accounts read further back.